The Experts below are selected from a list of 45 Experts worldwide ranked by ideXlab platform
Berit Berne - One of the best experts on this subject based on the ideXlab platform.
-
trioxsalen bath puva did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 swedish and finnish patients with psoriasis
British Journal of Dermatology, 1999Co-Authors: A Hannukselasvahn, K. Poikolainen, Matti Hannuksela, Eero Pukkala, B. Sigurgeirsson, B. Lindelöf, Berit Berne, Jaakko KarvonenAbstract:Trioxsalen bath PUVA did not increase the risk of nonmelanoma skin cancer in a joint analysis of 944 Swedish and Finnish patients with psoriasis.
-
Trioxsalen Bath PUVA Does Not Increase the Risk of Squamous Cell Skin Carcinoma: A Joint Analysis of 1124 Swedish and Finnish Patients Followed Up for 10 Years
Skin Cancer and UV Radiation, 1997Co-Authors: A. Hannuksela-svahn, K. Poikolainen, Eero Pukkala, B. Sigurgeirsson, B. Lindelöf, Berit Berne, M. Hannuksela, Jaakko KarvonenAbstract:Cancer incidence with special reference to nonmelanoma skin cancer was studied by combining the results of the two largest follow-up studies on trioxsalen (TMP) bath PUVA. The study cohort comprised 527 psoriasis patients treated at the Oulu University Hospital, Finland, in 1977–1988 and 597 patients treated with TMP bath PUVA at the Uppsala University Hospital, Sweden, in 1974–1985, of whom two thirds had psoriasis and the remaining on third other skin diseases. The average follow-up time in the combined cohort was 10 years. The observed and expected numbers of cases from the two studies were added up, and the combined standardized incidence ratios (SIR) were calculated. The expected numbers of cases were based on the national cancer incidence rates in the respective countries. Two cases of squamous cell skin carcinoma were found, while the expected number was 1.8 (SIR 1.1,95% CI 0.1-4.0). A fourfold or higher excess risk could be excluded. The overall risk of cancer was significantly increased in women (SIR 1.9,95% CI 1.4-2.6), but not in men. Kidney cancer (SIR 8.3,95% CI 2.7-19) and non-Hodgkin’s lymphoma (SIR 6.5,95% CI 1.4-19) were significantly more common than expected in women. In conclusion, the occurrence of squamous cell skin carcinoma was not increased in patients treated with TMP bath PUVA. The result indicates that TMP bath PUVA is a safer treatment than oral methoxsalen PUVA.
-
Comparison of the carcinogenic potential of trioxsalen bath PUVA and oral methoxsalen PUVA. A preliminary report.
Archives of dermatology, 1992Co-Authors: B. Lindelöf, B. Sigurgeirsson, Eva Tegner, Olle Larkö, Berit BerneAbstract:• Background and Design.— There is an increasing concern about the long-term carcinogenic effect of oral psoralen with long-wave UV radiation in the A range (PUVA). Most follow-up investigations indicate a definite risk of squamous cell carcinoma of the skin with long-term PUVA treatment. In a recently published study of 4799 Swedish patients who had received PUVA, it was noted that 833 patients who had received trioxsalen bath or oral trioxsalen did not show any increased risk of skin cancer in contrast to oral methoxsalen. This finding has been further investigated in this study. We compared four dermatologic university clinics in Sweden with regard to the carcinogenic potential of the PUVA regimen used. One clinic used trioxsalen bath PUVA exclusively and the other three used oral methoxsalen. Information on their PUVA-treated patients was collected and linked with information from the Swedish Cancer Registry to identify individuals with squamous cell carcinoma of the skin. Results.— A total of 18 squamous cell carcinomas of the skin were reported in 2975 PUVA-treated patients until 1987. The expected number was 3.1. The center using bath PUVA only had no increased risk of squamous cell carcinoma of the skin in contrast to the three centers using oral methoxsalen-PUVA. The increased risk for male subjects from those centers varied from six to 13 times that in the general population, but for female subjects a significant increased relative risk was found only at one center. Conclusion.— In this preliminary report, PUVA treatment with trioxsalen bath seems to be less carcinogenic than the oral dosage. However, differences in the patient populations might also have affected the outcome of the study. More information on this field is needed. (Arch Dermatol.1992;128:1341-1344)
Tapio Rantanen - One of the best experts on this subject based on the ideXlab platform.
-
Randomized half-side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis
Acta dermato-venereologica, 2004Co-Authors: Erna Snellman, Taras Klimenko, Tapio RantanenAbstract:The efficacy of trimethylpsoralen bath PUVA and UVB TL01 were compared in chronic plaque psoriasis. Patients were randomly assigned to receive UVB TL01 on one side and bath PUVA on the contra-lateral side. Altogether 17 patients received treatmentsand15 completedthetrial. The decrease in the PASI score was greater with UVB TL01 than PUVA. At the end of the treatment period, the difference was highly significant (pv0.001). The difference was already significant at week 3 (p~0.014). The relative median decrease in the PASI score was 77% (24‐100%) with UVB and 45% (8‐100%) with PUVA. The median cumulative UVB dose was 39.92 (range 13.95‐81.56) J/ cm 2 and the corresponding UVA dose was 8.06 (range 3.31‐12.51) J/cm 2 . All patients relapsed within 4 months. Narrowband UVB improved psoriasis clinically and statistically more efficiently than trimethylpsoralen bath PUVA, and UVB was better tolerated. Key words: controlled; phototherapy; photochemotherapy; Trioxysalen; TL01; ultraviolet.
-
Kinetics of phototoxicity in Trioxysalen bath psoralen plus ultraviolet A photochemotherapy.
Acta dermato-venereologica, 2001Co-Authors: Erna Snellman, Tapio RantanenAbstract:A Trioxysalen bath is a safe alternative to systemic 8-methoxypsoralen in long-term psoralen plus ultraviolet A (PUVA) treatment. The kinetics of its main side-effect, the strong phototoxicity, has not been thoroughly studied. This study determined the degree and persistence of phototoxicity after a single lOmin bath at a Trioxysalen concentration of 0.33 mg/l. The buttock skin of 16 healthy volunteers was irradiated with UVA lOmin, and 1, 3, 9 and 24h after the bath. The minimal phototoxic dose (MPD) was assessed 48, 72 and 96h after the bath. In general, the 96 h reading showed the lowest values of MPD; for example, a median of 0.14 J/cm 2 (95% confidence interval 0.10-0.14 J/cm 2 ) at sites irradiated 10 min after the bath. The values increased progressively with later irradiation, and the maximum dose applied, 18.32 J/cm 2 , failed to produce any redness when irradiation was given 24 h after the bath. Substantial phototoxicity persists up to at least 9 h after the Trioxysalen bath, making it wise for patients to avoid sunshine for at least the rest of the day.
B. Lindelöf - One of the best experts on this subject based on the ideXlab platform.
-
trioxsalen bath puva did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 swedish and finnish patients with psoriasis
British Journal of Dermatology, 1999Co-Authors: A Hannukselasvahn, K. Poikolainen, Matti Hannuksela, Eero Pukkala, B. Sigurgeirsson, B. Lindelöf, Berit Berne, Jaakko KarvonenAbstract:Trioxsalen bath PUVA did not increase the risk of nonmelanoma skin cancer in a joint analysis of 944 Swedish and Finnish patients with psoriasis.
-
Trioxsalen Bath PUVA Does Not Increase the Risk of Squamous Cell Skin Carcinoma: A Joint Analysis of 1124 Swedish and Finnish Patients Followed Up for 10 Years
Skin Cancer and UV Radiation, 1997Co-Authors: A. Hannuksela-svahn, K. Poikolainen, Eero Pukkala, B. Sigurgeirsson, B. Lindelöf, Berit Berne, M. Hannuksela, Jaakko KarvonenAbstract:Cancer incidence with special reference to nonmelanoma skin cancer was studied by combining the results of the two largest follow-up studies on trioxsalen (TMP) bath PUVA. The study cohort comprised 527 psoriasis patients treated at the Oulu University Hospital, Finland, in 1977–1988 and 597 patients treated with TMP bath PUVA at the Uppsala University Hospital, Sweden, in 1974–1985, of whom two thirds had psoriasis and the remaining on third other skin diseases. The average follow-up time in the combined cohort was 10 years. The observed and expected numbers of cases from the two studies were added up, and the combined standardized incidence ratios (SIR) were calculated. The expected numbers of cases were based on the national cancer incidence rates in the respective countries. Two cases of squamous cell skin carcinoma were found, while the expected number was 1.8 (SIR 1.1,95% CI 0.1-4.0). A fourfold or higher excess risk could be excluded. The overall risk of cancer was significantly increased in women (SIR 1.9,95% CI 1.4-2.6), but not in men. Kidney cancer (SIR 8.3,95% CI 2.7-19) and non-Hodgkin’s lymphoma (SIR 6.5,95% CI 1.4-19) were significantly more common than expected in women. In conclusion, the occurrence of squamous cell skin carcinoma was not increased in patients treated with TMP bath PUVA. The result indicates that TMP bath PUVA is a safer treatment than oral methoxsalen PUVA.
-
Comparison of the carcinogenic potential of trioxsalen bath PUVA and oral methoxsalen PUVA. A preliminary report.
Archives of dermatology, 1992Co-Authors: B. Lindelöf, B. Sigurgeirsson, Eva Tegner, Olle Larkö, Berit BerneAbstract:• Background and Design.— There is an increasing concern about the long-term carcinogenic effect of oral psoralen with long-wave UV radiation in the A range (PUVA). Most follow-up investigations indicate a definite risk of squamous cell carcinoma of the skin with long-term PUVA treatment. In a recently published study of 4799 Swedish patients who had received PUVA, it was noted that 833 patients who had received trioxsalen bath or oral trioxsalen did not show any increased risk of skin cancer in contrast to oral methoxsalen. This finding has been further investigated in this study. We compared four dermatologic university clinics in Sweden with regard to the carcinogenic potential of the PUVA regimen used. One clinic used trioxsalen bath PUVA exclusively and the other three used oral methoxsalen. Information on their PUVA-treated patients was collected and linked with information from the Swedish Cancer Registry to identify individuals with squamous cell carcinoma of the skin. Results.— A total of 18 squamous cell carcinomas of the skin were reported in 2975 PUVA-treated patients until 1987. The expected number was 3.1. The center using bath PUVA only had no increased risk of squamous cell carcinoma of the skin in contrast to the three centers using oral methoxsalen-PUVA. The increased risk for male subjects from those centers varied from six to 13 times that in the general population, but for female subjects a significant increased relative risk was found only at one center. Conclusion.— In this preliminary report, PUVA treatment with trioxsalen bath seems to be less carcinogenic than the oral dosage. However, differences in the patient populations might also have affected the outcome of the study. More information on this field is needed. (Arch Dermatol.1992;128:1341-1344)
Jaakko Karvonen - One of the best experts on this subject based on the ideXlab platform.
-
trioxsalen bath puva did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 swedish and finnish patients with psoriasis
British Journal of Dermatology, 1999Co-Authors: A Hannukselasvahn, K. Poikolainen, Matti Hannuksela, Eero Pukkala, B. Sigurgeirsson, B. Lindelöf, Berit Berne, Jaakko KarvonenAbstract:Trioxsalen bath PUVA did not increase the risk of nonmelanoma skin cancer in a joint analysis of 944 Swedish and Finnish patients with psoriasis.
-
Trioxsalen Bath PUVA Does Not Increase the Risk of Squamous Cell Skin Carcinoma: A Joint Analysis of 1124 Swedish and Finnish Patients Followed Up for 10 Years
Skin Cancer and UV Radiation, 1997Co-Authors: A. Hannuksela-svahn, K. Poikolainen, Eero Pukkala, B. Sigurgeirsson, B. Lindelöf, Berit Berne, M. Hannuksela, Jaakko KarvonenAbstract:Cancer incidence with special reference to nonmelanoma skin cancer was studied by combining the results of the two largest follow-up studies on trioxsalen (TMP) bath PUVA. The study cohort comprised 527 psoriasis patients treated at the Oulu University Hospital, Finland, in 1977–1988 and 597 patients treated with TMP bath PUVA at the Uppsala University Hospital, Sweden, in 1974–1985, of whom two thirds had psoriasis and the remaining on third other skin diseases. The average follow-up time in the combined cohort was 10 years. The observed and expected numbers of cases from the two studies were added up, and the combined standardized incidence ratios (SIR) were calculated. The expected numbers of cases were based on the national cancer incidence rates in the respective countries. Two cases of squamous cell skin carcinoma were found, while the expected number was 1.8 (SIR 1.1,95% CI 0.1-4.0). A fourfold or higher excess risk could be excluded. The overall risk of cancer was significantly increased in women (SIR 1.9,95% CI 1.4-2.6), but not in men. Kidney cancer (SIR 8.3,95% CI 2.7-19) and non-Hodgkin’s lymphoma (SIR 6.5,95% CI 1.4-19) were significantly more common than expected in women. In conclusion, the occurrence of squamous cell skin carcinoma was not increased in patients treated with TMP bath PUVA. The result indicates that TMP bath PUVA is a safer treatment than oral methoxsalen PUVA.
B. Sigurgeirsson - One of the best experts on this subject based on the ideXlab platform.
-
trioxsalen bath puva did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 swedish and finnish patients with psoriasis
British Journal of Dermatology, 1999Co-Authors: A Hannukselasvahn, K. Poikolainen, Matti Hannuksela, Eero Pukkala, B. Sigurgeirsson, B. Lindelöf, Berit Berne, Jaakko KarvonenAbstract:Trioxsalen bath PUVA did not increase the risk of nonmelanoma skin cancer in a joint analysis of 944 Swedish and Finnish patients with psoriasis.
-
Trioxsalen Bath PUVA Does Not Increase the Risk of Squamous Cell Skin Carcinoma: A Joint Analysis of 1124 Swedish and Finnish Patients Followed Up for 10 Years
Skin Cancer and UV Radiation, 1997Co-Authors: A. Hannuksela-svahn, K. Poikolainen, Eero Pukkala, B. Sigurgeirsson, B. Lindelöf, Berit Berne, M. Hannuksela, Jaakko KarvonenAbstract:Cancer incidence with special reference to nonmelanoma skin cancer was studied by combining the results of the two largest follow-up studies on trioxsalen (TMP) bath PUVA. The study cohort comprised 527 psoriasis patients treated at the Oulu University Hospital, Finland, in 1977–1988 and 597 patients treated with TMP bath PUVA at the Uppsala University Hospital, Sweden, in 1974–1985, of whom two thirds had psoriasis and the remaining on third other skin diseases. The average follow-up time in the combined cohort was 10 years. The observed and expected numbers of cases from the two studies were added up, and the combined standardized incidence ratios (SIR) were calculated. The expected numbers of cases were based on the national cancer incidence rates in the respective countries. Two cases of squamous cell skin carcinoma were found, while the expected number was 1.8 (SIR 1.1,95% CI 0.1-4.0). A fourfold or higher excess risk could be excluded. The overall risk of cancer was significantly increased in women (SIR 1.9,95% CI 1.4-2.6), but not in men. Kidney cancer (SIR 8.3,95% CI 2.7-19) and non-Hodgkin’s lymphoma (SIR 6.5,95% CI 1.4-19) were significantly more common than expected in women. In conclusion, the occurrence of squamous cell skin carcinoma was not increased in patients treated with TMP bath PUVA. The result indicates that TMP bath PUVA is a safer treatment than oral methoxsalen PUVA.
-
Comparison of the carcinogenic potential of trioxsalen bath PUVA and oral methoxsalen PUVA. A preliminary report.
Archives of dermatology, 1992Co-Authors: B. Lindelöf, B. Sigurgeirsson, Eva Tegner, Olle Larkö, Berit BerneAbstract:• Background and Design.— There is an increasing concern about the long-term carcinogenic effect of oral psoralen with long-wave UV radiation in the A range (PUVA). Most follow-up investigations indicate a definite risk of squamous cell carcinoma of the skin with long-term PUVA treatment. In a recently published study of 4799 Swedish patients who had received PUVA, it was noted that 833 patients who had received trioxsalen bath or oral trioxsalen did not show any increased risk of skin cancer in contrast to oral methoxsalen. This finding has been further investigated in this study. We compared four dermatologic university clinics in Sweden with regard to the carcinogenic potential of the PUVA regimen used. One clinic used trioxsalen bath PUVA exclusively and the other three used oral methoxsalen. Information on their PUVA-treated patients was collected and linked with information from the Swedish Cancer Registry to identify individuals with squamous cell carcinoma of the skin. Results.— A total of 18 squamous cell carcinomas of the skin were reported in 2975 PUVA-treated patients until 1987. The expected number was 3.1. The center using bath PUVA only had no increased risk of squamous cell carcinoma of the skin in contrast to the three centers using oral methoxsalen-PUVA. The increased risk for male subjects from those centers varied from six to 13 times that in the general population, but for female subjects a significant increased relative risk was found only at one center. Conclusion.— In this preliminary report, PUVA treatment with trioxsalen bath seems to be less carcinogenic than the oral dosage. However, differences in the patient populations might also have affected the outcome of the study. More information on this field is needed. (Arch Dermatol.1992;128:1341-1344)
